Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
Public ClinicalTrials.gov record NCT01922089. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Comparing Two Titration Regimens
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens.
Study identification
- NCT ID
- NCT01922089
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 498 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2013
- Primary completion
- Jul 31, 2014
- Completion
- Jul 31, 2014
- Last update posted
- Oct 14, 2015
2013 – 2014
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Anchorage | Alaska | 99508 | — |
| Novartis Investigative Site | Gilbert | Arizona | 85297 | — |
| Novartis Investigative Site | Tucson | Arizona | 85710 | — |
| Novartis Investigative Site | Anaheim | California | 92801 | — |
| Novartis Investigative Site | Torrance | California | 90502 | — |
| Novartis Investigative Site | Atlantis | Florida | 33462 | — |
| Novartis Investigative Site | Chiefland | Florida | 32626 | — |
| Novartis Investigative Site | Aurora | Illinois | 60504 | — |
| Novartis Investigative Site | Peoria | Illinois | 61602 | — |
| Novartis Investigative Site | Evansville | Indiana | 47714 | — |
| Novartis Investigative Site | Slidell | Louisiana | 70458 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55417 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110 | — |
| Novartis Investigative Site | Buffalo | New York | 14215 | — |
| Novartis Investigative Site | Laurelton | New York | 11422 | — |
| Novartis Investigative Site | Marion | Ohio | 43302 | — |
| Novartis Investigative Site | Oak Ridge | Tennessee | 37830 | — |
| Novartis Investigative Site | Dallas | Texas | 75231 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | Houston | Texas | 77094 | — |
| Novartis Investigative Site | Livingston | Texas | 77351 | — |
| Novartis Investigative Site | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01922089, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01922089 live on ClinicalTrials.gov.